| Field | Specification |
|---|---|
| Mfr No | |
| Formulation | |
| Product Type | |
| Shipping | |
| Species | |
| Storage | |
| UniProt # |
Product Description
HIV-based · VSV-G-pseudotyped · SIN=YesThe anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, 4-1BB and CD3ζ signaling domains . Note: This product transduces the same construct as the anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3ζ) (BPS Bioscience #78600), but differs in key aspects: 78601 is constructed with a SIN lentivector while 78600 is not. 78601 does not contain an antibiotic for selection while 78600 contains a puromycin selection so the transduced cells can be selected with puromycin.
Technical Details
| Vector Type | HIV-based, VSV-G-pseudotyped lentiviral vector |
|---|---|
| Payload / Construct | CD19 ScFv-CD8-4-1BB-CD3ζ · 3rd-Gen SIN |
| Target Antigen / Gene | CD19 (B-lymphocyte antigen CD19) |
| Signaling / Architecture | CD8 hinge & TM · 4-1BB · CD3ζ |
| Selection Marker | Puromycin |
| Reporter | None |
| Biosafety Level | BSL-2 |
| SIN Vector | Yes |
| Formulation | The lentiviruses were produced from HEK293T cells, concentrated, and resuspended in DMEM. |
| Supplied As | One vial (50 µl) of anti-CD19 CAR at a titer ≥ 108 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment. |
| Storage | −80°C; avoid repeated freeze-thaw cycles |
| Hazardous Shipping | UN3373 |
Applications
- Ideal as a positive control for anti-CD19 CAR evaluation in T cells Use in transduction optimization Use to generate anti-CD19 CAR-T cells for research use only, not for therapeutic purposes
Biosafety & Safety
The lentiviruses are produced with the third generation SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.
License & Regulatory
This CD19 ScFv-CD8-4-1BB-CD3ζ · 3rd-Gen SIN lentivirus is an HIV-based, VSV-G-pseudotyped vector, which confers broad tropism. It can transduce nearly all mammalian cell types, including primary T cells, non-dividing cells, and most established cell lines.
This product requires Biosafety Level 2 (BSL-2) facilities. Although the lentiviral particles are replication-incompetent, all local, institutional, and federal regulations must be observed. Appropriate personal protective equipment must be worn during handling.
Each lot is supplied at ≥10⁸ TU/ml. The exact titer value is lot-specific and is provided with each shipment. Functional titer may vary depending on the target cell type.
No. CAR expression is constitutive and does not require Cre recombinase. The CAR construct is driven by the internal promoter and will be expressed immediately after transduction into the target cells.
This lentivirus includes a Puromycin resistance gene, allowing selection of stably transduced cells by treatment with Puromycin at the appropriate concentration.
Store at −80°C immediately upon receipt. Avoid repeated freeze-thaw cycles, as viral titers decrease significantly with each cycle. For long-term storage, aliquot into single-use volumes before freezing. Short-term storage at 4°C (up to 1 week) is acceptable but may result in minor titer loss.
BioHippo offers customization and add-on services for selected products. Options may include:
- Custom formulations: Virus particles can be packaged in alternative formulations upon request (additional fees may apply).
- Custom titers: Higher-titer preparations may be available; contact us for feasibility and pricing.
- Bulk orders: Volume discounts are available for qualifying order quantities.
- Technical support: Our scientific team can assist with protocol optimization and troubleshooting.
For all customization inquiries, please use the contact form or email support@biohippo.com.
